A leader with 15 years big pharma experience and 5 years capital markets experience.

Experienced in operational and marketing roles at Pfizer Inc, Novartis and Zoetis.

A successful track record of product development, registration & product marketing launches, including commercialisation of numerous market leading blockbuster medicines.

Specialising in M&A, building high performance teams and cultures, corporate development and legal. She also completed the Pfizer Inc, 1-year internal leadership program in 2012.

Ms Phoenix has served on the Myopharm Board of Directors for 4 years and invested in almost all capital raises to date, while focussing on expanding Myopharm's clinical and commercial initiatives.

30 years in the global pharmaceuticals industry.

Previously Vice President of Global Business Development and Licensing at Novartis, and Non-Executive Director of SymBio Pharmaceuticals Limited.

Advisor to VOX Telehealth, BioHealthonomics Inc and Transparency Life Sciences.

Mr Abe has over 30 years extensive international experience as General Counsel to Japanese global corporations and in the global pharmaceuticals industry as business development, licensing and alliance management.

Previously General Counsel at Fast Retailing Co., Ltd and Kokuyo Co., Ltd and Corporate officer in charge of Global Business Development and Global Alliance Management at SymBio Pharmaceuticals Limited.

Currently COO at TAK-Circulator Corporation, CLO at nonpi Inc. Mr Abe holds a Batchelor of Law from Keio University.

James has 10 years’ experience in the research and development of pharmaceuticals, in both the inflammation and radiopharmaceutical domains. He has published peer reviewed articles on the chemical synthesis and preclinical evaluation of several clinically studied compounds.

Currently, he works as a consultant helping (radiopharmaceutical) companies develop GMP-compliant equipment and processes. Previously, he worked as an innovation consultant, helping life science startups acquire dilutive and non-dilutive funding.

James holds a PhD (Medicinal and Radiopharmaceutical Chemistry) and a BSc Honours (Chemistry) from the University of Queensland and a BSc (Corporate Finance) from the University of Western Australia.